New Cellular Therapy Gives Hope for Schizophrenia

T cells help control the immune system. Can they also help neurological illnesses such as schizophrenia? Campbell Neurosciences is working to find ways to help patients of this disease.

Campbell Neurosciences is a subsidiary of Therapeutic Solutions International (OTCPK:TSOI). Today the firm announced that recent data showed the effect of certain cells in an animal model of schizophrenia that resulted in suppression of multiple neurological manifestations of the condition. There was a clear association between increased numbers of T regulatory cells and therapeutic activity.

According to Dr. James Veltmeyer, Chief Medical Officer of the Company, "The interplay between the brain and the immune system is the foundation of Campbell Neurosciences, and I am very excited to lead the translation of this very relevant animal study into human clinical trials."

Campbell Neurosciences is focused on ending suicide using immunology and regenerative psychiatry and Therapeutic Solutions has 13 patent applications filed covering diagnostics and therapeutic solutions. Shares of Therapeutic Solutions were trading up almost 2% in mid-afternoon trade.